Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE).

Sharrack B, Saccardi R, Alexander T, Badoglio M, Burman J, Farge D, Greco R, Jessop H, Kazmi M, Kirgizov K, Labopin M, Mancardi G, Martin R, Moore J, Muraro PA, Rovira M, Sormani MP, Snowden JA; European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and EBMT (JACIE).

Bone Marrow Transplant. 2019 Sep 26. doi: 10.1038/s41409-019-0684-0. [Epub ahead of print]

PMID:
31558790
2.

Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment.

Lehmann HC, Burke D, Kuwabara S.

J Neurol Neurosurg Psychiatry. 2019 Sep;90(9):981-987. doi: 10.1136/jnnp-2019-320314. Epub 2019 Apr 16. Review.

PMID:
30992333
3.

Conduction block in immune-mediated neuropathy: paranodopathy versus axonopathy.

Garg N, Park SB, Howells J, Vucic S, Yiannikas C, Mathey EK, Nguyen T, Noto Y, Barnett MH, Krishnan AV, Spies J, Bostock H, Pollard JD, Kiernan MC.

Eur J Neurol. 2019 Aug;26(8):1121-1129. doi: 10.1111/ene.13953. Epub 2019 Apr 26.

PMID:
30882969
4.

Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy.

Khoo A, Frasca J, Schultz D.

Biomark Res. 2019 Feb 12;7:3. doi: 10.1186/s40364-019-0154-2. eCollection 2019. Review.

5.

IVIG efficacy in CIDP patients is not associated with terminal complement inhibition.

Keller CW, Quast I, Dalakas MC, Lünemann JD.

J Neuroimmunol. 2019 May 15;330:23-27. doi: 10.1016/j.jneuroim.2019.02.001. Epub 2019 Feb 10.

PMID:
30772754
6.

Multifocal visual evoked potentials in chronic inflammatory demyelinating polyneuropathy.

Graf J, Jansen L, Ingwersen J, Ringelstein M, Harmel J, Rybak J, Kolbe R, Rhöse L, Gemerzki L, Lee JI, Klistorner A, Guthoff R, Hartung HP, Aktas O, Albrecht P.

Ann Clin Transl Neurol. 2018 Jul 7;5(8):952-961. doi: 10.1002/acn3.593. eCollection 2018 Aug.

7.

Infantile-Onset Myelin Protein Zero-Related Demyelinating Neuropathy Presenting as an Upper Extremity Monoplegia.

Yiu EM, Wanigasinghe J, Mackay MT, Gonzales M, Nicholson GA, Ryan MM.

Semin Pediatr Neurol. 2018 Jul;26:52-55. doi: 10.1016/j.spen.2017.03.005. Epub 2017 Apr 1.

PMID:
29961519
8.

Vestibular impairment in chronic inflammatory demyelinating polyneuropathy.

Akdal G, Tanrıverdizade T, Şengün İ, Bademkıran F, Koçoğlu K, Yüceyar AN, Ekmekçi Ö, Karasoy H, Halmágyi GM.

J Neurol. 2018 Feb;265(2):381-387. doi: 10.1007/s00415-017-8712-8. Epub 2017 Dec 19.

PMID:
29260355
9.

Bilateral facial nerve palsies secondary to chronic inflammatory demyelinating polyneuropathy following adalimumab treatment.

Yao A, Chan H, Macdonell RAL, Shuey N, Khong JJ.

Clin Neurol Neurosurg. 2018 Jan;164:64-66. doi: 10.1016/j.clineuro.2017.11.001. Epub 2017 Nov 22.

PMID:
29179036
10.

Neurofascin-155 IGG4 Neuropathy: Pathophysiological Insights, Spectrum of Clinical Severity and Response To treatment.

Garg N, Park SB, Yiannikas C, Vucic S, Howells J, Noto YI, Mathey EK, Pollard JD, Kiernan MC.

Muscle Nerve. 2018 May;57(5):848-851. doi: 10.1002/mus.26010. Epub 2017 Nov 29.

PMID:
29130507
11.

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.

van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Mielke O, Durn BL, Cornblath DR, Merkies ISJ; PATH study group.

Lancet Neurol. 2018 Jan;17(1):35-46. doi: 10.1016/S1474-4422(17)30378-2. Epub 2017 Nov 6. Erratum in: Lancet Neurol. 2018 Jan;17 (1):26. Erratum in: Lancet Neurol. 2018 Aug;17(8):661.

PMID:
29122523
12.

NADPH oxidases as drug targets and biomarkers in neurodegenerative diseases: What is the evidence?

Sorce S, Stocker R, Seredenina T, Holmdahl R, Aguzzi A, Chio A, Depaulis A, Heitz F, Olofsson P, Olsson T, Duveau V, Sanoudou D, Skosgater S, Vlahou A, Wasquel D, Krause KH, Jaquet V.

Free Radic Biol Med. 2017 Nov;112:387-396. doi: 10.1016/j.freeradbiomed.2017.08.006. Epub 2017 Aug 12. Review.

13.

Autoantibody responses to nodal and paranodal antigens in chronic inflammatory neuropathies.

Mathey EK, Garg N, Park SB, Nguyen T, Baker S, Yuki N, Yiannikas C, Lin CS, Spies JM, Ghaoui R, Barnett MH, Vucic S, Pollard JD, Kiernan MC.

J Neuroimmunol. 2017 Aug 15;309:41-46. doi: 10.1016/j.jneuroim.2017.05.002. Epub 2017 May 13.

PMID:
28601286
14.

Differentiating lower motor neuron syndromes.

Garg N, Park SB, Vucic S, Yiannikas C, Spies J, Howells J, Huynh W, Matamala JM, Krishnan AV, Pollard JD, Cornblath DR, Reilly MM, Kiernan MC.

J Neurol Neurosurg Psychiatry. 2017 Jun;88(6):474-483. doi: 10.1136/jnnp-2016-313526. Epub 2016 Dec 21. Review.

15.

Postural tremor and chronic inflammatory demyelinating polyneuropathy.

Cao Y, Menon P, Ching-Fen Chang F, Mahant N, Geevasinga N, Fung VS, Vucic S.

Muscle Nerve. 2017 Mar;55(3):338-343. doi: 10.1002/mus.25253. Epub 2016 Dec 2.

PMID:
27421831
16.

Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy.

Devaux JJ, Miura Y, Fukami Y, Inoue T, Manso C, Belghazi M, Sekiguchi K, Kokubun N, Ichikawa H, Wong AH, Yuki N.

Neurology. 2016 Mar 1;86(9):800-7. doi: 10.1212/WNL.0000000000002418. Epub 2016 Feb 3.

17.

A case of chronic inflammatory demyelinating polyneuropathy with reversible alternating diaphragmatic paralysis: case study.

Haji K, Butler E, Royse C.

Crit Ultrasound J. 2015 Dec;7(1):16. doi: 10.1186/s13089-015-0033-5. Epub 2015 Oct 21.

18.

Chronic inflammatory demyelinating polyneuropathy with membranous nephropathy.

Wong AH, Kokubun N, Fukami Y, Miyaji K, Yuki N.

J Peripher Nerv Syst. 2015 Mar;20(1):63-6. doi: 10.1111/jns.12113. Review. No abstract available.

PMID:
25977098
19.

Office immunotherapy in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.

Dyck PJ, Taylor BV, Davies JL, Mauermann ML, Litchy WJ, Klein CJ, Dyck PJ.

Muscle Nerve. 2015 Oct;52(4):488-97. doi: 10.1002/mus.24707. Epub 2015 Aug 13. Review.

20.

Antibodies to neurofascin exacerbate adoptive transfer experimental autoimmune neuritis.

Yan W, Nguyen T, Yuki N, Ji Q, Yiannikas C, Pollard JD, Mathey EK.

J Neuroimmunol. 2014 Dec 15;277(1-2):13-7. doi: 10.1016/j.jneuroim.2014.09.012. Epub 2014 Sep 18.

PMID:
25262157

Supplemental Content

Loading ...
Support Center